

## Interim Report for the Six Months Ended 31 December 2023

### RESULTS FOR ANNOUNCEMENT TO THE MARKET

The following information is presented in accordance with ASX listing rule 4.2A.3 and should be read in conjunction with the attached EBOS Group Limited condensed consolidated interim unaudited financial statements for the six months ended 31 December 2023.

#### 1. DETAILS OF THE REPORTING PERIOD AND THE PREVIOUS CORRESPONDING PERIOD

Current period:	Six months ended 31 December 2023
Previous corresponding period	Six months ended 31 December 2022

This report and the attached Consolidated Financial Report are presented in Australian dollars, being the Group's presentation currency.

#### 2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

<b>Group Results (Unaudited)</b>	<b>31 Dec 2023 AUD \$000</b>	<b>31 Dec 2022 AUD \$000</b>	<b>Change %</b>
Revenue	<b>6,582,488</b>	6,145,722	7.1%
Earnings before depreciation, amortisation, net finance costs and tax expense (EBITDA)	<b>303,067</b>	289,180	4.8%
Depreciation and amortisation	<b>(66,343)</b>	(63,162)	(5.0%)
Earnings before interest and tax (EBIT)	<b>236,724</b>	226,018	4.7%
Profit before tax (PBT)	<b>191,958</b>	192,627	(0.3%)
Net profit after tax (NPAT)	<b>137,256</b>	137,591	(0.2%)
Net profit after tax (NPAT) attributable to owners of the Company	<b>136,175</b>	132,198	3.0%
Weighted average number of shares	<b>191,742</b>	190,018	0.9%
Basic EPS – (CPS)	<b>71.0</b>	69.6	2.1%
Net tangible asset backing per ordinary share – (\$)	<b>(\$4.24)</b>	(\$3.79)	
<b>Underlying EBITDA</b> (refer reconciliation below)	<b>313,167</b>	289,180	8.3%
<b>Underlying EBIT</b> (refer reconciliation below)	<b>259,914</b>	239,487	8.5%
<b>Underlying PBT</b> (refer reconciliation below)	<b>215,148</b>	206,096	4.4%
<b>Underlying Net profit after tax (NPAT) attributable to the owners of the Company</b> (refer reconciliation below)	<b>152,409</b>	141,626	7.6%
<b>Underlying EPS – (CPS)</b>	<b>79.5</b>	74.5	6.6%

<b>Dividends</b>	<b>Amount Per Share (NZ\$ Cents)</b>	<b>Franked amount per security to 30% tax rate</b>
Interim dividend payable 22 March 2024	57.0c	100%
Interim dividend – previous corresponding period	53.0c	100%
<b>Key dates for the 2024 Interim Dividend</b>		
Ex-dividend date		<b>29 February 2024</b>
Record date		<b>01 March 2024</b> (5.00pm NZST)
Dividend payment date		<b>22 March 2024</b>
<b>Other Comments</b>		
The interim dividend will be imputed to 25% for New Zealand tax resident shareholders and a supplementary dividend paid to eligible non-resident shareholders.		

### 3. RECONCILIATION OF REPORTED TO UNDERLYING EARNINGS

<b>Reconciliation of Reported to Underlying Earnings (Unaudited)</b>	<b>31 Dec 2023 AUD \$000</b>	<b>31 Dec 2022 AUD \$000</b>	<b>Change %</b>
<b>Reported EBITDA</b>	<b>303,067</b>	289,180	4.8%
Add back one-off items incurred during the period <sup>1</sup>	10,100	-	
<b>Underlying EBITDA</b>	<b>313,167</b>	289,180	8.3%
<b>Reported EBIT</b>	<b>236,724</b>	226,018	4.7%
Add back one-off items incurred during the period <sup>1</sup>	10,100	-	
Add back amortisation (non-cash) on LifeHealthcare PPA <sup>1</sup>	13,090	13,469	
<b>Underlying EBIT</b>	<b>259,914</b>	239,487	8.5%
<b>Reported PBT</b>	<b>191,958</b>	192,627	(0.3%)
Add back one-off items incurred during the period <sup>1</sup>	10,100	-	
Add back amortisation (non-cash) on LifeHealthcare PPA <sup>1</sup>	13,090	13,469	
<b>Underlying PBT</b>	<b>215,148</b>	206,096	4.4%
<b>Reported Net Profit after Tax (NPAT) attributable to owners of the Company</b>	<b>136,175</b>	132,198	3.0%
Add back one-off items incurred during the period <sup>1</sup> (net of tax and after non-controlling interests)	7,070	-	
Add back amortisation (non-cash) on LifeHealthcare PPA <sup>1</sup> (net of tax and after non-controlling interests)	9,164	9,428	
<b>Underlying Net Profit after Tax (NPAT) attributable to owners of the Company</b>	<b>152,409</b>	141,626	7.6%

<sup>1</sup> Underlying EBITDA, Underling EBIT, Underlying PBT and Underlying Net Profit after Tax attributable to the owners of the Company are non-GAAP measures. Underlying earnings for the 31 December 2023 period excludes the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets (\$13.1m pre tax, \$9.2m post tax) and one-off M&A costs (\$10.1m pre tax, \$7.1m post tax) primarily associated with a strategic transaction which did not proceed. Underlying earnings for the 31 December 2022 period excludes the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition PPA of finite life intangible assets (\$13.5m pre tax, \$9.4m post tax).

For supplementary comments on the Group's financial results refer to the Results Presentation, Letter to Shareholders and Media Release issued 21 February 2024.

#### **4. DIVIDENDS PAID AND DECLARED**

<b>Group Results (Unaudited)</b>	<b>Amount Per Share (NZ\$ Cents)</b>	<b>Amount Per Share (A\$ Cents)</b>	<b>Total Amount (A\$)</b>	<b>Date Paid / Payable</b>
<b>Dividends declared in respect of the year ending 30 June 2024</b>				
2024 interim dividend	57.0 cents	52.9 cents	\$101,443,000	22 March 2024
<b>Dividends paid in respect of the year ended 30 June 2023</b>				
2023 final dividend	57.0 cents	52.7 cents	\$100,879,000	29 September 2023
2023 interim dividend	53.0 cents	48.2 cents	\$92,610,000	17 March 2023
	110.0 cents	100.9 cents	\$193,489,000	

Dividends are approved by the Board in New Zealand dollars. Dividends recognised in the Statement of Changes in Equity are converted from New Zealand dollars to Australian dollars at the exchange rate applicable on the date the dividend was approved. Unrecognised dividends are converted at the exchange rate applicable on the reporting date.

#### **5. DIVIDEND REINVESTMENT PLAN**

The Company's dividend reinvestment plan ('DRP') will be operable for this dividend. The EBOS Board has approved a discount of 2.5% to the Volume Weighted Average Sales Price ('VWAP') for the shares to be issued under the DRP for the 2024 interim dividend.

#### **6. ENTITIES ACQUIRED**

Refer to Note 10 of the condensed consolidated interim unaudited financial statements.

## **7. ASSOCIATES AND JOINT VENTURES**

The Group equity accounted the following material associate entities at 31 December 2023.

<b>Name of business</b>	<b>Proportion of shares and voting rights</b>
Animates NZ Holdings Limited	50.00%
Good Price Pharmacy Franchising Pty Limited	44.18%
Good Price Pharmacy Management Pty Limited	44.18%

Income from the individual Associates has not been separately disclosed as it is considered immaterial. Total income from Investments in Associates for the six months ended 31 December 2023 was \$6,534,000 (2022: \$5,428,000).

## **8. FOREIGN ENTITIES**

The Consolidated Financial Statements are presented in Australian dollars and comply with International Financial Reporting Standards (“IFRS”).

## **9. INDEPENDENT AUDIT REVIEW**

The condensed consolidated interim financial statements have been reviewed by an independent auditor, and the auditor has given an unmodified review opinion.